Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 6, 2009, Pages 391-401

  Sorgel F ^a   Thyroff Friesinger, U ^b   Vetter, A ^b   Vens Cappell, B ^c   Kinzig, M ^a  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b Sandoz Biopharmaceuticals   (Germany)

^c Scope International   (Germany)

Author keywords

Biosimilar; Epoetin alfa; Epoetin beta; Erythropoiesis stimulating agents; Pharmacodynamics; Pharmacokinetics; Subcutaneous

Indexed keywords

BINOCRIT; ERYTHROPOIETIN ANTIBODY; HEMOGLOBIN; HX 575; IRON; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FATIGUE; FLU LIKE SYNDROME; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; POLYCYTHEMIA; RANDOMIZED CONTROLLED TRIAL;

EID: 67649967626     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47391     Document Type: Article

References (27)

1. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol. 2001; 57: 411-418
2. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. Basle, Hong Kong: Marcel Dekker Inc.; 1992.
3. CMP/ICH/281/95. http://www.emea.europa.eu/pdfs/human/ich/ 028195en.pdf. Accessed 19 January 2009.
4. CMP/ICH/381/95. http://www.emea.europa.eu/pdfs/human/ich/ 038195en.pdf. Accessed 19 January 2009.
5. de Andrade JR, Jove M, Landon G et al. Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthoped. 1996; 25: 533-542.
6. Delano BG, Lundin AP, Golansky R et al. Dialyzer urea and creatinine clearances not significantly changed in r-HuEPO treated maintenance hemodialysis (MD) patients. Kidney Int. 1988; 33: 219.
7. Egrie JC, Eschbach JW, McGuire T et al. Pharmacokinetics of recombinant human erythropoietin (rHuEPO) administered to hemodialysis (HD) patients. Kidney Int. 1988; 33: 262.
8. EMEA/CHMP/BWP/49348/2005. Accessed 19 January 2009: http://www.emea.europa.eu/pdfs/human/biosimilar/4934805en.pdf.
9. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111: 992-1000.
10. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985; 28: 1-5.
11. Eschbach JW, Egrie JC, DowningMRet al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316: 73-78.
12. Eschbach JW, Egrie JC, Downing MR et al. The use of recombinant human erythropoietin (r-HuEPO): Effect in end-stage renal disease (ESRD). In: Friedman EA, Beyer M, DeSanto NG, Giordano C (eds). Prevention of chronic uremia. Philadelphia, PA: Field and Wood Inc., 1989. p.148-155.
13. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA. 1990; 263: 825-830.
14. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am. 1996; 78: 62-72.
15. FDA Guidance for industry bioanalytical method validation. May 2001. Accessed 19 January 2009: http://www.fda.gov/CDER/GUIDANCE/ 4252fnl.htm.
16. Gascón P. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications. Oncologist. 2008; 13 (Suppl. 3): 4-10.
17. Goldberg MA, McCutchen JW, Jove M et al. A safety and efficacy comparison of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthoped. 1996; 25: 544-552.
18. Graber SE, Krantz SB. Erythropoietin and the control of red cell production. Annu Rev Med. 1978; 29: 51-66.
19. Halstenson CE, Macres M, Katz SA et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991; 50: 702-712.
20. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992; 30 (Suppl. 1): 37-43.
21. Hollander M, Wolfe DA. Nonparametric statistical methods. The two sample problem.NewYork:Wiley, 1973.
22. Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in predialysis patients: A double-blind placebo-controlled trial. Ann Int Med. 1989; 110: 108-114.
23. Melosky BL. Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol. 2008; 15 (Suppl. 1): S10-S15.
24. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40: 110-118.
25. Paganini E, Garcia J, Ellis P et al. Clinical sequelae of correction of anemia with recombinant human erythropoietin (r-HuEPO); Urea kinetics, dialyzer function and reuse. Am J Kidney Dis. 1988; 11: 16.
26. Stivelman J, Van Wyck D, Ogden D. Use of recombinant erythropoietin (r-HuEPO) with high flux dialysis (HFD) does not worsen azotemia or shorten access survival. Kidney Int. 1988; 33: 239.
27. Stone WJ, Graber SE, Krantz SB et al. Treatment of the anemia of pre-dialysis patients with recombinant human erythropoietin: A randomized, placebo-controlled trial. Am J Med Sci. 1988; 296: 171-179.